A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age (NCT07082829)
A Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of ORX142 in Healthy Adults, Single Doses of ORX142 in Healthy Older Adults, and a Single Dose Crossover, Proof-of-concept Study of ORX142 in Acutely Sleep-deprived Healthy Subjects
🩺 Plain-English Summary (8th-Grade Level)
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
Who can join: Review the eligibility criteria below.
Location: Site #1 — Lincoln, Nebraska
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Site #1 — Lincoln, Nebraska
- Site #2 — Eatontown, New Jersey
- Site #3 — New York, New York
📞 Contact the Study Coordinator
Phone: (617) 468-5770
Email: ORX142-0101study@centessa.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Excessive Daytime Sleepiness clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.